Summary
Definition
History and exam
Key diagnostic factors
- family history of childhood seizures
- staring episode, lasting 5 to 10 seconds; several times per day with no aura/postictal state
- childhood onset
- normal physical exam
- hyperventilation-induced seizure
Other diagnostic factors
- simple automatisms
- recent decline in school performance
- complex automatisms
- early onset (before age 4 years)
Risk factors
- family/genetic history of childhood absence epilepsy or juvenile myoclonic epilepsy
- acquired brain injury: for example, hypoxia-ischemia, trauma, infection
- other congenital inborn errors of metabolism, structural defects, chromosomal abnormalities
- developmental delay or intellectual disability
- female sex
Diagnostic tests
1st tests to order
- EEG
Tests to consider
- MRI brain
- testing for metabolic disorders (e.g., serum amino acids, urine organic acids, lactate pyruvate or specific enzymatic tests)
- cerebrospinal fluid and serum glucose
Emerging tests
- gene testing
Treatment algorithm
typical absence seizures without a history of generalized tonic-clonic seizures (childhood absence epilepsy)
typical absence seizures with a history of generalized tonic-clonic seizures (CAE, JAE, JME)
atypical absence seizures
refractory to treatment
Contributors
Authors
Judith L. Z. Weisenberg, MD
Assistant Professor of Neurology
Washington University Medical School
St. Louis
MO
Disclosures
JLZW states that she has no competing interests.
Acknowledgements
Dr Judith L. Z. Weisenberg would like to gratefully acknowledge Dr Michael Wong, a previous contributor to this topic.
Disclosures
MW declares that he has no competing interests.
Peer reviewers
Anita Devlin, MBBS, MD
Consultant Paediatric Neurologist
Royal Victoria Infirmary
NHS Foundation Trust
Newcastle-upon-Tyne
UK
Disclosures
AD and two epilepsy nurses from her department have been reimbursed by UCB Pharma, the manufacturer of levetiracetum, for attending several conferences. One of the epilepsy nurses received a one-off sponsorship payment from UCB Pharma to cover the initial set-up costs of the adolescent epilepsy support group. One epilepsy nurse has been reimbursed by Cyberonics, the manufacturer of vagal nerve stimulators, for attending one or more conferences.
Cigdem Akman, MD
Division of Pediatric Neurology
Columbia University College of Physicians and Surgeons
New York
NY
Disclosures
CA declares that he has no competing interests.
Angus A. Wilfong, MD
Associate Professor
Pediatrics and Neurology
Baylor College of Medicine
Medical Director
Comprehensive Epilepsy Program
Texas Children's Hospital
Houston
TX
Disclosures
AAW declares that he has no competing interests.
Helen Cross, MB, ChB, PhD, FRCP, FRCPCH
Head of Neurosciences Unit
The Prince of Wales’s Chair of Childhood Epilepsy
National Centre for Young People with Epilepsy
London
UK
Disclosures
HC has received research funds from HAS, Epilepsy Research UK, SHS, and the Milk Development Council. She has received funding for an epilepsy training fellowship from UCB and Eisai. She has also received travel funding from Eisai, UCB, and GlaxoSmithKline.
References
Key articles
Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017 Apr;58(4):522-30.Full text Abstract
Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. 2010 Apr;51(4):676-85. Abstract
Rosenow F, Wyllie E, Kotagal P, et al. Staring spells in children: descriptive features distinguishing epileptic and nonepileptic events. J Pediatr. 1998 Nov;133(5):660-3. Abstract
Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010 Mar 4;362(9):790-9.Full text Abstract
Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia. 2013 Jan;54(1):141-55.Full text Abstract
Bergey GK. Evidence-based treatment of idiopathic generalized epilepsies with new antiepileptic drugs. Epilepsia. 2005;46 Suppl 9:161-8. Abstract
Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs I: treatment of new-onset epilepsy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2018 Jul 10;91(2):74-81.Full text Abstract
Nordli DR Jr. Idiopathic generalized epilepsies recognized by the International League Against Epilepsy. Epilepsia. 2005 Nov 18;46(suppl 9):48-56.Full text Abstract
Reference articles
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
Differentials
- Daydreaming
- Attention deficit hyperactivity disorder (ADHD)
- Complex partial epilepsy of frontal or temporal lobe origin
More DifferentialsGuidelines
- Epilepsies in children, young people and adults
- Antiseizure medication withdrawal in seizure-free patients: practice advisory update summary
More GuidelinesPatient information
Absence seizures in children
More Patient informationLog in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer